Intrinsic Alpha

Boundless Bio, Inc.

NASDAQ:BOLD

Biotechnology

Healthcare
$2.40 +85.71%

+$1.20 today

Market cap
$56.67M
Beta
0.97
P/E (TTM)
-1.0
EPS (TTM)
-$2.50
52W Low $0.96High $2.75

Volume 0.15M

Average 0.22M

BOLD Net Income

Bottom-line profit after all expenses, interest, and taxes.

Boundless Bio, Inc.NASDAQ: BOLD

Net Income Β· Q1 FY2026 Β· quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$13.56M, compared with -$15.76M a year earlier. Trailing-twelve-month net income was -$55.99M.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate of -$53.22M (+8.6%) for the fiscal year ending Dec 2026, a slowdown from the +11.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.56M-5.2% QoQ
Last fiscal yearDec 2025
-$58.2M+11.0% YoY
LTMMar 2026
-$55.99M+14.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.0%+14.2%+0.3 pp
1 year+11.0%+8.6%-2.4 pp
3-year CAGRβ€”β€”β€”
5-year CAGRβ€”β€”
10-year CAGRβ€”β€”

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD Β· from the income statement

Latest Β· FY2025
(58.2M) USD
Year-over-year change
+11.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BOLD compares with its peers on the latest reported figures

  • BOLD's LTM Mar 2026 net income of -$55.99M is the lowest of the 4 companies compared; the peer median is -$7.82M.
  • Its year-over-year change of +14.8% is the lowest of 4, against a peer median of +83.8%.
BOLD Competitors Peer median
Net Income for BOLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M +155.6%β€”61.9%
RLYBRallybio CorporationLTM Mar 2026-$7.82M +83.8%β€”911.1%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$34.55M +23.8%β€”β€”
BOLDBoundless Bio, Inc.LTM Mar 2026-$55.99M +14.8%β€”β€”
Peer median (excluding BOLD) -$7.82M+83.8%β€”486.5%

Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0001.09M1.25M
Gross Profit000(1.09M)(1.25M)
Gross Marginβ€”β€”β€”β€”β€”
Research & Development19.28M37.16M42.64M55.27M44.85M
Selling, General & Admin6.02M9.31M12.16M18M18.71M
Operating Expenses25.3M46.47M54.8M72.18M62.3M
Depreciation & Amortization682K942K957K1.09M1.25M
EBITDA(24.53M)(44.96M)(48.48M)(64.28M)(56.95M)
EBITDA Marginβ€”β€”β€”β€”β€”
Operating Income(25.3M)(46.47M)(54.8M)(73.27M)(63.55M)
Operating Marginβ€”β€”β€”β€”β€”
Interest Income96K668K5.28M7.89M5.36M
Interest Expense00000
Other Income / Expenses91K568K5.36M7.9M5.36M
Income Before Tax(25.21M)(45.9M)(49.43M)(65.36M)(58.2M)
Pre-Tax Marginβ€”β€”β€”β€”β€”
Income Tax Expense00000
Net Income(25.21M)(45.9M)(49.43M)(65.36M)(58.2M)
Net Marginβ€”β€”β€”β€”β€”
EPS (Basic)(1.13)(2.06)(2.22)(3.85)(2.60)
EPS (Diluted)(1.13)(2.06)(2.22)(3.85)(2.60)
Weighted Avg Shares22.24M22.24M22.24M16.98M22.36M
Weighted Avg Shares (Diluted)22.24M22.24M22.24M16.98M22.36M

Boundless Bio, Inc.

NASDAQ:BOLD

Intrinsic Alpha fair value

Locked

Current Price

$2.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.